Table 1. Lists a summary of the TKI’s that are FDA approved in advanced HCC.

Trial name	Author	No. of patients	Study arm	ECOG	Child-Pugh score	BCLC stage	Primary endpoint
SHARP	Llovet et al. (5)	602	Sorafenib vs. placebo (first-line setting)	0 to 2	A	B	OS: 10.7 vs. 7.9 months; hazard ratio (HR) =0.69; P<0.001; TTP: 4.1 vs. 4.9 months, P=0.77
REFLECT	Kudo et al. (8)	954	Lenvantinib vs. sorafenib (first-line setting)	0 or 1	A	B or C	OS: lenvatinib 13.6 months (95% CI: 12.1–14.9) vs. sorafenib (12.3 months, 95% CI: 10.4–13.9) (HR =0.92, 95% CI: 0.79–1.06)
CELESTIAL	Abou-Alfa et al. (9)	707	Cabozantinib vs. placebo (second-line setting)	0 or 1	A		OS: cabozantinib 10.2 vs. 8.0 months with placebo (HR =0.76; 95% CI: 0.63–0.92; P=0.005)
RESORCE	Bruix et al. (10)	567	Regorafenib vs. placebo (second-line setting)	0 or 1	A	B or C	OS: 10.6 months (95% CI: 9.1–12.1) for regorafenib vs. 7.8 months (6.3–8.8) for placebo, HR =0.63 (95% CI: 0.50–0.79; P<0.0001)

TKI, tyrosine kinase inhibitors; HCC, hepatocellular carcinoma; OS, overall survival; HR, hazard ratio.